Know EDS.

What EDS is

The Ehlers-Danlos Syndromes (EDS) are a group of 13 heritable disorders of connective tissue. Connective tissue is the material that holds the body together, tendons, ligaments, skin, blood vessels, gut wall, uterus, cornea. When collagen and related proteins are made or assembled abnormally, tissues become more elastic, more fragile, and more prone to damage.

EDS is not one disease. It is 13 conditions with different genes, different tissues affected, and different prognoses. Roughly 95% of clinically-diagnosed EDS is hypermobile-type (hEDS); the other 12 subtypes are much rarer. Vascular EDS (vEDS) is the subtype with reduced life expectancy from arterial rupture; the others are variously disabling but not directly life-shortening in most patients.

EDS is not caused by weakness, deconditioning, or anything the patient did. It is a genetic condition present from birth. The joint hypermobility and tissue features are structural, not something that can be "trained away." Management is about protecting what tissue you have, treating the comorbidities that stack on top, and building a life around the constraint.

The 13 subtypes

The 2017 international classification recognises 13 EDS subtypes. In practical terms:

• Hypermobile EDS (hEDS). The most common by far (roughly 95% of clinical diagnoses). No confirmed gene yet. Diagnosed against the 2017 clinical criteria. Covered in depth below.
• Classical EDS (cEDS). COL5A1 or COL5A2 genes. Marked skin hyperextensibility, atrophic scarring, and generalised joint hypermobility.
• Classical-like EDS (clEDS). TNXB gene. Skin hyperextensibility but no atrophic scarring; generalised hypermobility.
• Vascular EDS (vEDS). COL3A1 gene. The dangerous one, covered in its own section below.
• Kyphoscoliotic EDS (kEDS). PLOD1 or FKBP14 genes. Congenital scoliosis, severe muscle hypotonia, joint hypermobility.
• Arthrochalasia EDS (aEDS). COL1A1 or COL1A2 (specific mutations). Severe generalised joint hypermobility, congenital hip dislocation.
• Dermatosparaxis EDS (dEDS). ADAMTS2 gene. Severe skin fragility.
• Brittle Cornea Syndrome. ZNF469 or PRDM5 genes. Thin, fragile cornea; risk of rupture.
• Spondylodysplastic EDS. Several genes. Short stature, skeletal dysplasia.
• Musculocontractural EDS. CHST14 or DSE genes. Congenital contractures, distinctive facial features.
• Myopathic EDS. COL12A1 gene. Muscle weakness, joint contractures.
• Periodontal EDS. C1R or C1S genes. Severe early-onset periodontitis.
• Cardiac-valvular EDS. COL1A2 gene (specific mutations). Severe progressive cardiac valve problems.

All subtypes except hEDS have identified genes and can be confirmed with genetic testing. If a rare subtype is suspected, genetics referral is the pathway. If the picture is straightforward hypermobility with typical comorbidities and no red flags, most clinicians go through the hEDS or HSD diagnostic process without immediate genetics.

hEDS specifically

Because hEDS accounts for the vast majority of clinical EDS, most of this reference is oriented to it. Key points:

• hEDS is currently the only EDS subtype without a confirmed genetic marker. Diagnosis is clinical against the 2017 criteria.
• The 2017 criteria are strict. Patients with symptomatic hypermobility who don't meet the full criteria are diagnosed with Hypermobility Spectrum Disorder (HSD), covered on the HSD reference on this site.
• hEDS and HSD share the same clinical spectrum and get the same management.
• The hEDS-gene search is active; if it's found, the diagnostic framework will shift again.
• Inheritance is autosomal dominant: 50% risk of passing it to each child.

Vascular EDS: the urgent subtype

Vascular EDS (vEDS) is rare but life-threatening. Caused by mutations in the COL3A1 gene, which codes for type III collagen (the major collagen in arteries and hollow organs). Without functional type III collagen, arteries and organ walls can rupture without warning.

Features that should prompt a genetics referral:

• Family history of unexplained arterial rupture, aortic dissection, or organ rupture (especially in young adults).
• Family history of sudden death without explanation.
• Thin, translucent skin where veins are prominently visible (particularly on the chest, abdomen, and inner arms).
• Easy bruising disproportionate to activity.
• Facial features: thin nose, thin upper lip, small chin, prominent eyes.
• Small joint hypermobility (fingers) without the generalised hypermobility of hEDS.
• Early varicose veins, pneumothorax, or bowel rupture without clear cause.

EDS vs HSD

Since the 2017 international nomenclature reform, patients with symptomatic joint hypermobility who don't meet the strict 2017 hEDS criteria are diagnosed with Hypermobility Spectrum Disorder (HSD). Key points about the relationship:

• HSD is not a milder version of hEDS. It sits on the same clinical spectrum.
• Management is identical: hypermobility-literate PT, joint protection, pain management, comorbidity treatment.
• Comorbidities cluster the same way (POTS, MCAS, GI dysmotility, endometriosis, ADHD/autism).
• Disability paperwork uses the same processes.
• The distinction is diagnostic-technical, not clinical.

The HSD reference on this site covers HSD-specific framing (the "you don't quite meet criteria" gaslighting pattern, the four HSD subtypes, spectrum diagnosis) in more depth. If you have EDS, the HSD page is worth reading to understand the community you're part of.

Causes and biology

EDS is genetic. Most subtypes have identified genes coding for collagen or related proteins:

• Collagen genes. Types I, III, and V collagen are the main proteins. Different mutations produce different subtypes.
• Collagen-processing enzymes. Genes coding for the enzymes that assemble collagen (like ADAMTS2, PLOD1) produce specific subtypes when mutated.
• Related structural proteins. TNXB (tenascin XB) and others contribute to specific subtypes.
• hEDS mystery. The most common subtype has no confirmed gene; the search continues. Possibly polygenic or involving genes not yet fully characterised.

The downstream biology matters: collagen is present in every body system, which is why EDS reaches so far beyond joints. Blood vessels, gut wall, uterus, cornea, skin, tendons, ligaments, cartilage all rely on collagen. When collagen is structurally different, every one of those systems can behave differently.

Related conditions

EDS clusters heavily with POTS and MCAS (the trifecta), and with several other conditions covered in depth in Chapter 6:

• POTS (roughly half of hEDS patients meet criteria on proper testing)
• MCAS (mast cell activation)
• Craniocervical instability (CCI) and tethered cord
• Gastroparesis and other GI dysmotility
• Endometriosis, adenomyosis, pelvic-floor dysfunction
• TMJ (temporomandibular joint) disorder
• Dental fragility, gum recession
• Anxiety, depression, ADHD, autism, PTSD
• Chronic fatigue with or without ME/CFS overlap
• Fibromyalgia overlap

Support for family and loved ones

The hardest thing for the people around an EDS patient to understand is how the same person can be "flexible and fine" one day and dislocating a shoulder reaching for the kettle the next. The tissue is structurally different; day-to-day capacity varies with sleep, hormones, stress, hydration, and pure luck of movement.

What helps: taking cancellations gracefully, learning the early flare signs, being the calm voice during a subluxation, doing physical tasks that involve joints the patient shouldn't stress (heavy lifting, high shelves, awkward angles). What hurts: implying they should just build up strength (they should, but not the way you might think), suggesting yoga (the wrong kind can hurt), and treating good days as evidence the illness is mild.

The diagnostic odyssey

The average path to hEDS diagnosis in patient surveys is 10+ years and 10+ clinicians. The story repeats: a kid who was always "flexible" and praised for it, a teenager with growing pains that never quite went away, a young adult with unexplained joint problems and fatigue, a decade of being told it's fibromyalgia or anxiety or "just being hypermobile," and eventually a POTS diagnosis or a serious injury or a chance encounter with an EDS-literate clinician forces the pieces together.

The moment of diagnosis is often described as bittersweet: relief that there's a name and an explanation, grief for the years lost to misdiagnosis, anger at the clinicians who dismissed the symptoms, and a specific dread about telling loved ones. Many patients also describe a moment of clarity: parents, siblings, or children who suddenly make sense. EDS is autosomal dominant in most forms; the family tree usually has more of it than anyone realised.

Medical gaslighting

EDS patients have their own particular gaslighting patterns:

• "You're just double-jointed." (Hypermobility is not a party trick when it comes with subluxations and chronic pain.)
• "You should stretch more." (Aggressive stretching in hypermobile joints often makes things worse.)
• "You just need to build up strength." (Yes, but the way generic gym strength programmes don't do; hypermobility-literate PT does.)
• "It's growing pains, they'll go away." (For a child with hEDS, they don't.)
• "You're too flexible to have joint pain." (Hypermobility is a cause of joint pain, not a defence against it.)
• "Your MRI is normal, so the pain isn't real." (Standard MRI often misses instability, which is the actual problem.)
• "You're too anxious to have these physical symptoms." (Anxiety is often a consequence, not the cause.)

The clinicians most likely to recognise EDS early are rheumatologists with hypermobility interest, EDS-clinic specialists, and (increasingly) autonomic-medicine specialists working from the POTS side. General practice and general orthopaedics are the most common sources of prolonged misdiagnosis.

Invisible illness

EDS is largely invisible until it isn't. A patient can look completely fine sitting in a coffee shop, then dislocate a finger picking up a mug. Over time, subtle signs accumulate (skin bruises easily, joints crack constantly, posture is unusual, mobility aids appear situationally), but for most patients the disease is largely internal.

The invisibility drives specific harms: friends and family assume they must be exaggerating on bad days, employers assume they should be able to do the same tasks as everyone else, clinicians in single appointments see a person who "looks fine." The lived reality is largely private, negotiated day by day inside the body.

Impact on identity

EDS often has a specific identity impact because it's genetic and lifelong. Patients describe realising that the fatigue, joint problems, and social difficulty they've had since childhood weren't personality flaws or weakness. Simultaneously, they realise that this is who they've always been, not something that came from outside. The integration work is different from acquired chronic illnesses: less about mourning who you were and more about accepting who you always were.

The community often talks about "the click": the moment when the diagnosis reorganises everything. It usually happens over months, not one afternoon.

Isolation

Social isolation in EDS has several drivers: cancelled plans due to flares, difficulty tolerating some environments (crowds, standing, hot places if POTS is comorbid), embarrassment about visible symptoms (mobility aids, splints), and the exhaustion of explaining a rare disease over and over. Many patients find their most sustaining community online, particularly on Instagram and TikTok where the EDS community has been unusually strong at making the reality visible.

Mental health

Anxiety, depression, PTSD, ADHD, and autism are all over-represented in the EDS community. Some of this is consequence (years of dismissal, chronic pain, unpredictable body) and some is shared underlying biology (connective tissue in nervous system, shared genetic architecture, central sensitisation). Treatment matters. Choose medications carefully; some EDS patients are exquisitely sensitive to standard doses, and local anaesthetics can be less effective in some (relevant for dental work). SNRIs, low-dose tricyclics, and low-dose abilify are often better-tolerated than SSRIs in this population.

EDS reaches every body system because collagen is everywhere. The list below is comprehensive, not a checklist. No patient has every symptom, and severity varies enormously across patients and across time within one patient.

Joint hypermobility and instability

The signature feature. Joints move beyond normal range because ligaments are structurally more elastic. Consequences:

• Subluxations. Partial dislocations, where the joint moves partway out of alignment then back. Common in shoulders, fingers, hips, knees, ribs, TMJ. Often multiple per day for moderate-to-severe patients.
• Dislocations. Full joint dislocation. Some patients can reduce their own; some need medical help. Repeated dislocations progressively damage the joint capsule.
• Chronic pain around joints. Not from the joint itself but from surrounding tissue overworking to stabilise loose joints.
• Injury with minimal trauma. Sprains and ligament tears from everyday movement.
• Postural changes. Compensatory postures develop over years; alignment issues stack.
• Early osteoarthritis. Cumulative joint damage often shows up as early OA in some patients.

The Beighton score measures nine hypermobility criteria (0-9). It's the entry criterion for hEDS but a poor measure of disability. Some highly-Beighton-positive patients have little disability; some lower-scoring patients have severe disability. What matters clinically: subluxation frequency, pain, and functional impact.

Pain

Chronic pain is one of the biggest quality-of-life issues in EDS. Drivers include:

• Mechanical joint pain from subluxations and overuse.
• Muscle pain from constant micro-stabilising of loose joints.
• Nerve pain from small fibre neuropathy (present in a subset).
• Nociplastic pain overlap with fibromyalgia (heavily comorbid).
• Headaches and migraines (over-represented).
• Abdominal pain from GI dysmotility.
• Pelvic pain from pelvic-floor dysfunction and endometriosis.
• Central sensitisation on top of all the above.

Pain management in EDS is layered: PT (the foundation), local approaches (heat, ice, TENS, topical NSAIDs, lidocaine patches), oral medications (paracetamol, cautious NSAID use, SNRIs like duloxetine, low-dose amitriptyline, gabapentinoids), and coordinated pain-clinic involvement for severe cases. Long-term opioids are generally discouraged.

Skin and tissue

Skin features vary by subtype but many patients notice:

• Soft, velvety skin texture.
• Skin that stretches easily and springs back slowly.
• Easy bruising, disproportionate to any injury.
• Atrophic scarring ("cigarette paper" scars that widen over time).
• Slow wound healing.
• Stretch marks in unusual locations without pregnancy or weight change.
• Piezogenic papules (small skin bumps at the heels when standing).
• Prominent visible veins on chest and abdomen (particularly in vEDS).

Tissue fragility extends beyond skin. Hernias (especially incisional), organ prolapse (uterine, rectal, bladder), and prolapsed valves in veins are all more common. Surgical wounds may not hold sutures well; surgeons should know about EDS in advance.

Autonomic dysfunction and POTS

Autonomic symptoms are near-universal in EDS. Most patients meet POTS criteria on a properly-done stand test:

• Standing heart rate spikes.
• Lightheadedness, presyncope, occasional fainting.
• Brain fog on standing (from reduced cerebral perfusion).
• Heat intolerance.
• Post-meal crashes.
• Temperature regulation problems.
• Chronic fatigue that tracks with orthostatic load.

Treating the POTS often produces the biggest single functional improvement. Foundations: 2-3L fluid, 8-10g sodium, waist-high compression. Medications: beta blockers or ivabradine, midodrine, fludrocortisone, pyridostigmine. The POTS reference on this site covers the full picture.

GI dysmotility

Connective tissue is throughout the gut wall. GI symptoms in EDS are common and routinely under-recognised:

• Gastroparesis (delayed stomach emptying).
• Slow-transit constipation.
• Rectal prolapse, particularly with straining.
• IBS-pattern symptoms.
• Gastroesophageal reflux disease.
• Small bowel bacterial overgrowth (SIBO).
• Nausea, early satiety, post-meal crashes.
• Increased sensitivity to certain foods.

Workup: gastric emptying study, colonoscopy, upper endoscopy where indicated, dietary review. Treatment: smaller more frequent meals, sometimes prokinetics (erythromycin, prucalopride, motegrity), pelvic-floor PT for prolapse and constipation, dietary work with a hypermobility-aware dietitian.

Dental and TMJ

Dental fragility and TMJ (temporomandibular joint) problems are heavily over-represented in EDS:

• TMJ subluxations and clicking.
• Jaw pain and headaches from TMJ dysfunction.
• Gum recession, sometimes disproportionate to hygiene.
• Early tooth wear and cracking.
• Increased sensitivity to dental work.
• Local anaesthetics can be less effective in a subset of EDS patients (relevant for dental work).
• Periodontal EDS specifically: severe early-onset periodontitis.

Find an EDS-aware dentist where possible. Regular checks, custom mouthguards (for TMJ and grinding), and a lower threshold for extra anaesthetic all help.

Gynaecological

The reproductive tract is connective tissue too. Common features in patients with uteruses:

• Heavy or painful periods.
• Endometriosis (heavily over-represented).
• Adenomyosis.
• Pelvic-floor dysfunction (incontinence, prolapse, pain with intercourse).
• Uterine prolapse, particularly postpartum.
• Cyclical symptom flares (hormones affect joint laxity across the cycle).
• Complicated pregnancies (preterm labour, precipitous delivery, tissue fragility during delivery).

Fatigue

Chronic, disproportionate fatigue is one of the most common EDS symptoms. Drivers:

• The metabolic cost of stabilising loose joints all day.
• Autonomic dysfunction (POTS overlap).
• Poor sleep (pain, position issues).
• Anaemia (over-represented, particularly iron-deficient).
• Central sensitisation.
• Nutritional deficiencies (particularly with GI involvement).
• ME/CFS overlap in a meaningful subset (especially post-viral onset).

The Beighton score

The Beighton score is a 9-point scale for generalised joint hypermobility:

• 1 point each for passive dorsiflexion of each little finger beyond 90° (2 possible)
• 1 point each for passive apposition of each thumb to the flexor forearm (2 possible)
• 1 point each for hyperextension of each elbow beyond 10° (2 possible)
• 1 point each for hyperextension of each knee beyond 10° (2 possible)
• 1 point for forward flexion of the trunk with knees straight so that the palms rest flat on the floor

Age-adjusted thresholds for "generalised hypermobility":

• Pre-pubertal children: 6/9 or higher
• Pubertal men and women up to age 50: 5/9 or higher
• Adults over 50: 4/9 or higher

The Beighton has real limitations: it misses hypermobility in joints not tested (hips, shoulders, TMJ, ankles), doesn't measure instability or pain, and hypermobility naturally decreases with age. The 5-part questionnaire (Grahame-Hakim) and history of prior hypermobility can supplement.

2017 hEDS criteria

The 2017 international consortium criteria for hEDS require ALL of the following:

Criterion 1: Generalised joint hypermobility (per Beighton thresholds above).

Criterion 2: Two of the following three features:

• Feature A: Systemic manifestations of a generalised connective tissue disorder (a checklist of 12 items covering skin texture, atrophic scarring, striae, piezogenic papules, hernias, dental crowding, arachnodactyly, arm span vs height, mitral valve prolapse, aortic root dilatation; 5 or more of 12 required).
• Feature B: Positive family history (one or more first-degree relatives meeting the criteria).
• Feature C: Musculoskeletal complications (chronic musculoskeletal pain in 2+ limbs for 3+ months, chronic widespread pain for 3+ months, or recurrent joint dislocations/instability without trauma).

Criterion 3: Exclusion of alternative diagnoses. Other heritable and acquired connective tissue disorders, autoimmune rheumatologic conditions, and other rarer subtypes of EDS must be ruled out.

Patients who meet Criterion 1 but not the full package usually receive a diagnosis of HSD (Hypermobility Spectrum Disorder). Management is the same. The HSD reference on this site covers HSD-specific framing.

Genetic testing

hEDS has no confirmed genetic marker; genetic testing does not diagnose hEDS. Genetic testing is diagnostic for the other 12 subtypes and is worth pursuing when:

• Family history suggests vEDS (arterial rupture, sudden death, characteristic features): COL3A1 testing.
• Skin findings suggest classical EDS: COL5A1/COL5A2 testing.
• Congenital features suggest a rare subtype (kyphoscoliotic, arthrochalasia, dermatosparaxis): specific gene panels.
• Cardiac valve involvement: cardiac-valvular EDS panel.
• Severe periodontitis in a young patient: periodontal EDS panel.

Panel tests covering multiple EDS-related genes are increasingly available. Cost and insurance coverage vary. A genetics counsellor can help interpret results and family screening implications.

Differential diagnosis

Conditions to consider before finalising an EDS diagnosis:

• Marfan syndrome (FBN1 gene; aortic root dilatation, ectopia lentis, characteristic body proportions).
• Loeys-Dietz syndrome (aortic aneurysm risk; TGF-beta pathway genes).
• Osteogenesis imperfecta (frequent fractures, blue sclerae, dentinogenesis).
• Stickler syndrome (eye involvement, hearing loss, palatal features).
• Congenital contractural arachnodactyly (Beals syndrome).
• Autoimmune rheumatologic disease (Sjögren's, lupus, RA).
• Simple joint hypermobility without systemic features (benign; doesn't need active management).
• HSD (Hypermobility Spectrum Disorder; the most common alternative diagnosis for patients not meeting hEDS criteria).

Physiotherapy: the centrepiece

Hypermobility-literate physiotherapy is the single highest-leverage intervention in EDS. It is not the same as general PT. Key principles:

• Strength before stretch. Hypermobile joints don't need more range; they need better stabilisation. Aggressive stretching often makes things worse.
• Small ranges, high frequency. Short range, high-repetition exercises build endurance in the small stabilising muscles.
• Joint-neutral position. Learning where the joint's neutral is and staying there under load.
• Proprioception training. EDS patients often have poor joint position sense; retraining it reduces subluxation frequency.
• Progressive loading. Slow progression respecting the flare threshold.
• Consistency over intensity. 20 minutes most days beats 90 minutes twice a week.

Named approaches with strong community endorsement:

• The Muldowney Protocol. A comprehensive structured PT programme published in Kevin Muldowney's book. Well-tested in the EDS community.
• Jeannie Di Bon's Integral Movement Method. Movement-focused approach specifically for hypermobility. YouTube channel and paid programme; the free content is substantial.
• Chimera Health. PT-led YouTube channel with hypermobility-specific content.
• Certified EDS-aware physiotherapists. Increasingly available through the Ehlers-Danlos Society clinician directory.

Pain management

Layered approach:

• Foundation: PT. Reduces the mechanical drivers of pain.
• Local approaches. Heat, ice, TENS, topical NSAIDs, lidocaine patches, kinesiology tape.
• First-line oral: paracetamol/acetaminophen. Usually safe; can be layered with topical NSAIDs.
• Cautious NSAID use. Watch GI (EDS patients are already at higher GI risk) and cardiovascular. Short courses, lowest effective dose.
• Neuromodulators. Amitriptyline, nortriptyline (low-dose), duloxetine (SNRI), gabapentinoids for neuropathic and central-sensitisation pain.
• Muscle relaxants. Cyclobenzaprine, tizanidine occasionally.
• Opioids. Generally discouraged as first-line. Short courses for acute injuries only. Long-term opioid use in EDS is associated with poor outcomes.
• Interventional pain approaches. Trigger-point injections, occipital nerve blocks (for headache), radiofrequency ablation for specific pain generators. Consider carefully in EDS given tissue fragility.
• Coordinated pain-clinic involvement for severe cases.

Treat the comorbidities

Most of the functional gain in EDS comes from treating comorbid conditions in parallel with the EDS itself. Priority screens:

• POTS. Stand test in every EDS patient; roughly half meet criteria. Treatment lifts a whole functional level. See the POTS reference.
• MCAS. Screen for flushing, food reactions, drug sensitivities, dermatographism. Trial H1/H2 antihistamines.
• Sleep apnea. Over-represented in EDS. A sleep study is worth it.
• Iron deficiency and B12. Ferritin under 75 is functionally deficient.
• Thyroid disease. TSH and free T4.
• Endometriosis. Consider in any menstruating EDS patient with pelvic pain or heavy periods.
• GI dysmotility. Gastric emptying study if symptoms suggest.
• CCI (craniocervical instability) or tethered cord. Consider when neurological or dysautonomic symptoms disproportionate to POTS alone.
• ADHD, autism. Neuropsychiatric assessment where late-recognised traits fit.

Surgery in EDS

Surgery in EDS is different in several ways:

• Tissue heals more slowly. Recovery times are typically 1.5-2x standard.
• Sutures don't hold as well. Wound dehiscence is more common. Surgeons often use extra sutures, keep sutures in longer, and choose different suture techniques.
• Local anaesthetics. Can be less effective in a subset of EDS patients (relevant for dental work, minor procedures, epidurals).
• Post-op pain. Often higher and longer.
• Hypermobility-related orthopaedic surgery. Mixed outcomes; sometimes helpful (severe shoulder instability, hip labral tears), sometimes not. Ask about outcomes in hypermobile patients specifically.
• vEDS. Non-urgent surgery is often avoided; when needed, requires vascular surgery experience and specific precautions.

Tell every surgeon and anaesthetist about your EDS in advance. Bring the Ehlers-Danlos Society's surgical guidance to appointments where relevant.

What helps versus what harms

Experimental and emerging

• hEDS gene research. Multiple groups searching; if a gene is found, the diagnostic framework will change substantially. Timeline uncertain.
• Prolotherapy and PRP injections. Popular in some hypermobility communities. Weak clinical evidence; mixed patient reports. Not recommended by major EDS organisations without more data.
• Celiprolol for vEDS. Beta-blocker with evidence for reducing arterial events in vEDS. Standard-of-care in some centres.
• Emerging autonomic and MCAS treatments. Ivabradine, mestinon, low-dose naltrexone all used off-label for the comorbidities.
• GLP-1 medications (tirzepatide, semaglutide). Anecdotal reports from EDS/MCAS patients of dramatic whole-body pain reduction (313↑ discussion, one patient describing 70% pain reduction within hours). Mechanism unclear; possibly anti-inflammatory. Not a mainstream EDS treatment; interesting signal worth following.
• CCI surgical fusion. Considered in severe craniocervical instability; controversial; irreversible. Multidisciplinary opinion essential.
• Tethered cord surgery. Where imaging and neurology support the diagnosis, surgical release can help. Also controversial and irreversible.

Tools, apps, and the kit patients actually use

Tracking and monitoring

• Rox. The companion app this reference is built alongside. Tracks joint incidents (subluxations, dislocations), PT consistency, pain patterns, and the POTS / MCAS / GI comorbidities that stack on top. Turns months of data into the coordinated-care picture EDS needs. App Store.
• Wearable HR / HRV for the POTS-overlap subset (Apple Watch, Garmin, Whoop, Oura, Polar chest strap).
• Symptom diaries. Simple tracking of joint incidents, pain, PT adherence, sleep, cycle for menstruating patients.

Joint protection

• Compression garments. Waist-high compression for POTS; joint-specific compression for hypermobile hands, elbows, knees.
• Silver ring splints or Oval-8 splints. Finger stabilisers; well-loved by the community.
• Kinesiology tape. Provides proprioceptive feedback; short-term use.
• Ergonomic setup. Split keyboard, vertical mouse, monitor arm, sit-stand desk, footrest, saddle chair.
• Supportive footwear. Firm arch support, cushioned heel. Custom orthotics for a subset.
• Mobility aids. Rollators with seats, folding cane-seats, wheelchairs for travel and crowds. Situational use preserves joints.

Home setup

• Shower stool (IKEA BÄSINGEN is the community favourite for looking like normal furniture).
• Bidet or handheld shower for patients with wrist/shoulder problems.
• Grabber tools for high shelves.
• Sock aids, button hooks for finger-heavy tasks.
• Ergonomic kitchen tools (Y-peelers, spring-loaded scissors, jar openers).
• Firm but not hard mattress and pillow setup that supports the neck without forcing extension. The r/ehlersdanlos community (883↑ discussion) particularly recommends buckwheat-hull pillows for neck instability: firm, even, non-settling support that reduces neck clenching, tossing, and snoring.

Finding the right clinician

• Ehlers-Danlos Society clinician directory (international).
• Ehlers-Danlos Support UK resources.
• Specialist hypermobility clinics at major academic centres.
• Hypermobility-certified physiotherapists (Jeannie Di Bon has a directory).
• EDS-aware dentists and anaesthetists (harder to find; ask around).

Prognosis

EDS prognosis varies by subtype:

• hEDS. Not life-shortening. Disability picture is highly variable. Most patients find a workable baseline with consistent PT, joint protection, and comorbidity treatment. Many describe improvement over years once the right pieces are in place.
• HSD. Same as hEDS.
• Classical EDS. Not life-shortening in most cases. Skin fragility and scarring are ongoing concerns.
• Vascular EDS. Reduced life expectancy from arterial and organ rupture; median around 50 in older cohorts, though modern surveillance and celiprolol improve this significantly.
• Other rare subtypes. Prognosis varies; kyphoscoliotic can have severe spinal complications; brittle cornea has vision-threatening potential; cardiac-valvular can be life-shortening from valve failure.

For the majority of EDS patients (hEDS and HSD), the prognosis picture is: manageable if treated well, damaging if not. The gap between well-managed and unmanaged EDS is large.

Pacing and joint protection

The daily engineering of EDS life is about managing joint load. Practical strategies:

• Pacing. Break tasks into short blocks with recovery. Similar principle to ME/CFS pacing, applied to joint capacity as well as energy.
• Joint neutral positions. Learning where the joint's neutral is and staying near it under load. Applies to sitting posture, sleeping position, lifting technique.
• Load management. Distributing loads across multiple joints rather than one. Backpack instead of shoulder bag. Both hands instead of one for heavy things.
• Prophylactic bracing. Wearing joint supports before you need them, particularly during high-load tasks.
• Rest joints proactively. A joint that has done a lot today gets less tomorrow, not more.
• Adaptive tools. Grabber, jar opener, sock aid, dressing stick, ergonomic kitchen tools.
• Environmental design. Bedside-everything, no high shelves you use regularly, sit-stand desk, appropriate chair.
• Sleep setup. Firm but not hard mattress, appropriate pillow, ideally not on your stomach.

Work and disability

The Work picture in EDS depends heavily on severity, subtype, and role. Practical realities:

• Mild EDS: often compatible with most desk-based or remote work. Ergonomic setup essential; typing and mouse use are joint-intensive.
• Moderate EDS: often needs part-time, remote, or accommodated work. Frequent flare-related absences.
• Severe EDS: full-time work is often unsustainable. Focus shifts to disability paperwork.

Accommodations that help: ergonomic equipment (split keyboard, vertical mouse, sit-stand desk, monitor arm, appropriate chair, footrest), flexibility around appointments, permission to use mobility aids without comment, remote-work options during flares, flexible scheduling.

Disability paperwork: EDS counts under disability legislation in most jurisdictions. Document joint incidents, pain, missed work, comorbidity load. Start early during a flare; documentation is harder later. The Ehlers-Danlos Society has clinician-facing letter templates.

Fertility and pregnancy

Pregnancy in EDS is possible with planning. Key considerations:

• Fertility. Generally normal in most subtypes.
• vEDS pregnancy. Carries a serious risk of arterial and uterine rupture. Specialist obstetric care essential. Some patients choose not to attempt pregnancy given the risk.
• hEDS/HSD pregnancy. Increased risk of preterm labour, precipitous delivery, pelvic-girdle pain (often severe), joint laxity worsening (hormonal effect on connective tissue), postpartum joint instability, pelvic-floor damage.
• Precipitous delivery. Labour can be unusually fast in hEDS; some patients don't reach hospital in time. Discuss birth planning early.
• Anaesthesia. Epidurals can be technically different in EDS; some patients report reduced local-anaesthetic response. Discuss with the anaesthetist in advance.
• Postpartum. Joint instability often worse for months postpartum (hormones + physical stress). Pelvic-floor PT starting early helps.
• Inheritance. Autosomal dominant for most subtypes: 50% risk of passing it to each child. Genetics counselling helps couples make informed decisions.

Children with EDS

Recognising EDS early matters because:

• Kids diagnosed and supported early do better long-term than kids blamed for being "clumsy" or "attention-seeking."
• Growing pains that don't resolve, frequent injuries, and disproportionate fatigue in a "flexible" child warrant a Beighton score.
• PE accommodations, note-taking help, and access to school medical care make a large difference.
• Kids benefit from age-appropriate PT and understanding their body before adolescence brings additional challenges.

Adolescents with EDS often have a specific window of instability (growth spurts + hormonal changes) followed by improvement in early adulthood. The picture at 14 is not necessarily the picture at 24.

Adapting life around the illness

The patients who live well with EDS almost universally describe the same arc: years of pushing through and getting hurt, hitting a wall, accepting the disease as a constraint to design around, then finding meaningful life inside the constraint. Practical engineering that helps:

• Environment designed around the illness: ergonomic everything, bedside-everything, no high shelves you use daily, mobility aids by default for high-cost tasks.
• Consistent PT built into daily routine.
• Cyclic tracking (for menstruating patients) to predict high-symptom days.
• Pre-emptive rest before high-load events; recovery days after.
• Community with other EDS patients who understand without explanation.
• One or two people who will keep believing the illness on good days.
• Regular check-ins on the comorbidities that stack on top (POTS, MCAS, GI, mental health).

EDS rarely travels alone. The comorbidity cluster is the same whether the label is hEDS or HSD. Treating each condition separately, in parallel with the EDS itself, is usually what moves a patient's functional level.

The trifecta: EDS + POTS + MCAS

The three conditions co-occur so often that clinicians treat them as one triad. Roughly half of hEDS/HSD patients meet POTS criteria on a proper stand test; a substantial minority also meet MCAS criteria. A patient with all three needs all three treated.

POTS

Postural Orthostatic Tachycardia Syndrome overlaps heavily with EDS. Standing heart-rate spikes, lightheadedness, brain fog on standing, heat intolerance, post-meal crashes. Treatment: fluids (2-3L), sodium (8-10g), waist-high compression, beta blockers or ivabradine for tachycardia, midodrine for pooling, fludrocortisone for blood volume. The POTS reference on this site covers the full picture.

MCAS

Mast Cell Activation Syndrome features flushing, hives, food and drug reactions, GI symptoms, and unexplained reactions to medications. Diagnosis is largely clinical (tryptase and urinary methylhistamine have imperfect sensitivity). Treatment: H1 antihistamines (cetirizine, fexofenadine), H2 antihistamines (famotidine), mast-cell stabilisers (ketotifen, cromolyn), low-histamine diet for the responsive subset. Many EDS patients report significant improvement across multiple systems on antihistamine trials.

Craniocervical instability and tethered cord

Two serious, often-missed, sometimes-surgical conditions in the EDS space:

Craniocervical instability (CCI). Instability at the junction between the skull and upper cervical spine due to weak ligaments. Symptoms: severe headaches, brain fog, dysautonomia, sleep disturbance, neurological signs. Diagnosis often requires upright MRI or dynamic imaging; surgical fusion is considered for severe cases. Controversial (irreversibility, mixed outcomes) and warrants multidisciplinary opinion, but real and undertreated.

Tethered cord syndrome. The spinal cord attached abnormally at the base, causing tension with movement. Symptoms: back pain, leg symptoms, bladder or bowel changes, worsening dysautonomia. Diagnosis via MRI (though standard MRI can miss it) and neurology assessment. Surgical release is sometimes helpful; also irreversible and warrants careful decision-making.

Both are worth investigating when neurological or autonomic symptoms are disproportionate to POTS alone. Dr. Gilete in Barcelona is one of the most-cited surgeons in the community for CCI fusion, particularly for patients who travel internationally for the procedure.

Gastroparesis and GI dysmotility

Slow gastric emptying and other motility disorders are heavily over-represented in EDS. Gastric emptying study when symptoms suggest. Treatment: smaller more frequent meals, prokinetics (erythromycin, prucalopride, motegrity), dietary work with a hypermobility-aware dietitian. Pelvic-floor PT for constipation and prolapse.

Endometriosis

Endometriosis is heavily over-represented in EDS patients with uteruses. The shared pattern includes chronic pelvic pain, heavy or painful periods, cyclical GI symptoms, and pain with intercourse. Endometriosis diagnosis is via laparoscopy; treatment can include hormonal management, excision surgery (by an endometriosis specialist, not general gynecology), and pain management. Adenomyosis is also over-represented.

TMJ and dental

TMJ (temporomandibular joint) disorder is common in EDS. Jaw pain, clicking, subluxation, headaches, chronic muscle tension. Treatment: custom mouthguard (particularly for grinding), TMJ-specific physiotherapy, sometimes intra-articular injections. Dental fragility (gum recession, tooth wear, sensitivity, potential local-anaesthetic difficulty) benefits from an EDS-aware dentist and regular checks.

ADHD, autism, AuDHD

ADHD and autism (often together, "AuDHD") are heavily over-represented in the EDS community. Patient surveys suggest a substantial proportion of EDS patients have at least one, often diagnosed late. The mechanisms probably include shared genetic architecture, connective-tissue involvement in the nervous system, and central sensitisation.

Late recognition matters. Many EDS patients spent decades masking sensory sensitivities and executive-function differences before a diagnosis in adulthood. Treatment (medication for ADHD, accommodations for both) often changes life quality significantly. Rox and other tools that help with executive function are useful adjuncts.

Mental health comorbidities

Anxiety, depression, PTSD, and OCD are over-represented in the EDS community. Drivers are both shared biology (central sensitisation, autonomic dysregulation) and the specific stresses of living with a poorly-recognised chronic illness. Treatment is worthwhile. Medication choice matters:

• SSRIs sometimes worsen POTS and can be poorly tolerated.
• SNRIs (duloxetine, venlafaxine) often work well for pain + depression overlap.
• Low-dose tricyclics (amitriptyline, nortriptyline) help sleep and pain simultaneously.
• Low-dose abilify is a growing option for treatment-resistant depression in the EDS / ME/CFS space.
• Benzodiazepines are often poorly tolerated and habit-forming; use cautiously.

The current scientific picture

EDS is understood as a heterogeneous group of connective tissue disorders. The mechanistic picture varies by subtype:

• Classical, vascular, and other identified-gene subtypes. Mutations in collagen genes (COL1A1/2, COL3A1, COL5A1/2) or collagen-processing enzymes (ADAMTS2, PLOD1) directly disrupt structural proteins.
• hEDS. The mechanism is not fully understood. The hEDS gene search continues; possibly polygenic. Increased tenascin XB haploinsufficiency has been proposed but not confirmed.
• Comorbidity biology. The autonomic dysfunction, MCAS, and neurodivergence overlaps suggest shared underlying architecture involving connective tissue, autonomic regulation, and central nervous system function.
• Downstream mechanisms. Small fibre neuropathy is documented in a subset. Central sensitisation contributes to pain amplification.

The hEDS gene search

Finding a hEDS gene would transform care: definitive diagnosis instead of clinical criteria, family screening, targeted therapies, potentially reclassifying HSD. Active research groups include:

• The hEDS Genetic Evaluation (HEDGE) Study run by the Ehlers-Danlos Society, ongoing multi-year effort.
• Norris Lab and others.
• Multiple international consortia.

Progress is slow because hEDS is common enough that a simple single-gene explanation is unlikely; the disease may be polygenic, with multiple contributing variants of small effect. Timeline to a definitive answer is uncertain.

Historical timeline

Active research directions

• hEDS gene identification. Multiple groups; HEDGE study is the largest.
• hEDS as an immune-dysregulation condition. Recent work from The Norris Lab and ICR (InVitro Cell Research) (260↑ discussion, referenced by the Ehlers-Danlos Society) points toward hEDS potentially being an immune-dysregulation condition rather than purely a connective-tissue disorder, which would meaningfully change how the disease is understood and treated. Watch this space.
• Autonomic dysfunction biology. The POTS overlap has driven research into shared mechanisms.
• Small fibre neuropathy in EDS. Prevalence, diagnosis, treatment.
• MCAS in EDS. Prevalence, diagnostic criteria, treatment response.
• Celiprolol for vEDS. Further evidence for slowing arterial events.
• PT trials. Comparative trials of different hypermobility PT approaches.
• CCI and tethered cord research. Diagnosis, surgical outcomes.
• Pregnancy outcomes. Registries and prospective data on EDS pregnancy management.
• Endometriosis-EDS link. Shared mechanisms, treatment response.
• Neurodivergence-EDS link. ADHD/autism prevalence and shared architecture.

Key sources worth knowing

• The Ehlers-Danlos Society (US-based, international scope). The definitive international EDS organisation. Clinical guidelines, patient resources, clinician directory, HEDGE study, physio programme certification.
• Ehlers-Danlos Support UK. UK-based charity with strong patient resources.
• The 2017 International Classification papers. The current diagnostic framework, published in the American Journal of Medical Genetics. Worth being familiar with if you're pursuing a diagnosis.
• Kevin Muldowney's book ("Living Life to the Fullest with Ehlers-Danlos Syndrome"). The Muldowney Protocol for PT.
• Jeannie Di Bon's Integral Movement Method. Books, YouTube, paid programme.
• The Ehlers-Danlos Society YouTube channel. Conference recordings, patient education.
• The Bendy Bodies Podcast. EDS + POTS specialist podcast; strong on the trifecta.

Content creators worth knowing

These are the names that come up again and again in r/ehlersdanlos and adjacent hypermobility communities, sorted by what the community actually shares. The Reddit citation under each card is the thread the recommendation traces back to.

Organisations and leadership

Clinicians and researchers

Physiotherapy and movement

Podcasts and tools

The contested zone

Resources and community

• r/ehlersdanlos on Reddit. The main English-language EDS community.
• Facebook EDS groups. Country- and topic-specific.
• Ehlers-Danlos Society local chapters and annual conferences.
• The Zebra Network and other patient-led support communities.
• EDS awareness month (May). Community events, education, advocacy.

Where to start if you've just been diagnosed

1. Rule out vEDS with any suspicious features; get genetics referral if warranted.
2. Find a hypermobility-literate physiotherapist. Start with 20 minutes most days.
3. Get a stand test for POTS; treat it if present.
4. Screen for MCAS, sleep apnea, iron deficiency, thyroid, endometriosis.
5. Get an EDS-aware dentist. Book a checkup and mention the diagnosis.
6. Build a joint-protection plan and pain-management plan.
7. Start disability paperwork early during a flare.
8. Find one supportive community and one reliable information source.
9. Read the 2017 international criteria so you understand what you were diagnosed against.
10. If you have children, consider whether they need assessment too.

About this reference

This is a living document. It will be updated as new research emerges and as community-sourced Reddit research on EDS becomes available. The medical claims here are drawn from the 2017 international classification, the Ehlers-Danlos Society clinical resources, published EDS literature, and adjacent literature on POTS and MCAS. None of this is personal medical advice. For your situation specifically, talk with an EDS-aware clinician.